Immune response and adverse events to influenza vaccine in cancer patients undergoing PD-1 blockade

被引：0
|
作者：
Rothschild, S. I. [1 ]
Balmelli, C. [1 ]
Kaufmann, L. [2 ]
Stanczak, M. [2 ]
Syedbasha, M. [2 ]
Vogt, D. [2 ]
Gautschi, O. [3 ]
Egli, A. [4 ]
Zippelius, A. [1 ]
Laeubli, H. [1 ]
机构：
[1] Univ Spital Basel, Dept Internal Med, Med Oncol, Basel, Switzerland
[2] Univ Basel, Dept Biomed, Basel, Switzerland
[3] Cantonal Hosp Lucerne, Dept Med Oncol, Luzern, Switzerland
[4] Univ Spital Basel, Clin Microbiol, Basel, Switzerland
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
112P-PR
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Immune response and adverse events to influenza vaccine in cancer patients undergoing PD-1 blockade.
    Laubli, Heinz Philipp
    Balnnelli, Cathrin
    Kaufmann, Lukas
    Stanczak, Michal
    Syedbasha, Mohammedyaseen
    Vogt, Dominik
    Mueller, Beat
    Gautschi, Oliver
    Stenner, Frank
    Zippelius, Alfred
    Egli, Adrian
    Rothschild, Sacha
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] Immune-Related Thyroid Adverse Events Predict Response to PD-1 Blockade in Patients with Melanoma
    Dawidowska, Anna
    Jagodzinska-Mucha, Paulina
    Kosela-Paterczyk, Hanna
    Jaczewska, Sylwia
    Sobczuk, Pawel
    Chelstowska, Monika
    Kowalska, Maria
    Badziak-Sterczewska, Honorata
    Poleszczuk, Jan
    Rutkowski, Piotr
    Lugowska, Iwona
    CANCERS, 2022, 14 (05)
  • [3] Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade
    Stroud, Chipman R. G.
    Hegde, Aparna
    Cherry, Cynthia
    Naqash, Abdul R.
    Sharma, Nitika
    Addepalli, Srikala
    Cherukuri, Sulochana
    Parent, Teresa
    Hardin, Jessica
    Walker, Paul
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (03) : 551 - 557
  • [4] Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events
    Laeubli, Heinz
    Balmelli, Catharina
    Kaufmann, Lukas
    Stanczak, Michal
    Syedbasha, Mohammedyaseen
    Vogt, Dominik
    Hertig, Astrid
    Mueller, Beat
    Gautschi, Oliver
    Stenner, Frank
    Zippelius, Alfred
    Egli, Adrian
    Rothschild, Sacha I.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [5] Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade.
    Stroud, Chipman Robert Geoffrey
    Cherry, Cynthia R.
    Nagash, Abdul Rafeh
    Sharma, Nitika
    Cherukuri, Sulochana Devi
    Parent, Teresa
    Hardin, Jessica
    Walker, Paul R.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations
    Yang, Jiqiao
    He, Xiujing
    Lv, Qing
    Jing, Jing
    Shi, Hubing
    FRONTIERS IN PHARMACOLOGY, 2019, 10
  • [7] PD-1 Immune Checkpoint Blockade Promotes Therapeutic Cancer Vaccine to Eradicate Lung Cancer
    Kadam, Pournima
    Sharma, Sherven
    VACCINES, 2020, 8 (02) : 1 - 13
  • [8] Prognostic Signature of Response to PD-1 Immune Checkpoint Blockade in Lung Cancer
    Ding, Juan
    Sun, Tingting
    Yao, Juan
    Zheng, Ni
    Lu, Rong
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2023, 37 (02): : 617 - 628
  • [9] Immune-related adverse events predict responses to PD-1 blockade immunotherapy in hepatocellular carcinoma
    Lu, Lianghe
    Xing, Kaili
    Wei, Wei
    Ling, Yihong
    Li, Peng
    Li, Shaohua
    Wang, Yan
    Xie, Dan
    Guo, Rongping
    Cai, Muyan
    INTERNATIONAL JOURNAL OF CANCER, 2021, 149 (04) : 959 - 966
  • [10] Tocilizumab for the Management of Immune Mediated Adverse Events Secondary to PD-1 Blockade: Overall Survival Analysis
    Stroud, C. R. G.
    Hegde, A.
    Naqash, A. R.
    Cherry, C.
    Parent, T.
    Hardin, J.
    Walker, P. R.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1554 - S1555
12345